W L Nichols

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)
    W L Nichols
    Special Coagulation Laboratory, Division of Hematopathology, Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, MN, USA
    Haemophilia 14:171-232. 2008
  2. ncbi Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay
    D Chen
    Special Coagulation Laboratory, Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    J Thromb Haemost 9:1993-2002. 2011
  3. ncbi Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
    M A Elliott
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 76:1154-62. 2001
  4. ncbi Autoimmune factor VIII inhibitors
    R K Pruthi
    Department of Internal Medicine and Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Hematol 6:314-22. 1999
  5. ncbi Sensitivity and specificity of denaturing high-pressure liquid chromatography for unknown protein C gene mutations
    M R Taliani
    Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Genet Test 5:39-44. 2001
  6. ncbi A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry
    D Chen
    Special Coagulation Laboratory, Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Thromb Haemost 6:323-30. 2008
  7. ncbi Fechtner syndrome: physiologic analysis of macrothrombocytopenia
    R D McBane
    Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Blood Coagul Fibrinolysis 11:243-7. 2000
  8. ncbi Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates
    D Dingli
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Haemophilia 8:629-34. 2002
  9. ncbi Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor
    J E Sadler
    Howard Hughes Medical Institute, Washington University, St Louis, MO 63110, USA
    J Thromb Haemost 4:2103-14. 2006

Detail Information

Publications9

  1. ncbi von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)
    W L Nichols
    Special Coagulation Laboratory, Division of Hematopathology, Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, MN, USA
    Haemophilia 14:171-232. 2008
    ..The NHLBI Web site (http://www.nhlbi.nih.gov/guidelines/vwd) has a more detailed document, a synopsis of these recommendations, and patient education information...
  2. ncbi Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay
    D Chen
    Special Coagulation Laboratory, Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    J Thromb Haemost 9:1993-2002. 2011
    ..Laboratory diagnosis of von Willebrand disease (VWD) requires accurate measurement of plasma von Willebrand factor (VWF) activity...
  3. ncbi Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
    M A Elliott
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 76:1154-62. 2001
    ..While uncommon, TTP and HUS are of considerable clinical importance because of their abrupt onset, fulminant clinical course, and high morbidity and mortality in the absence of early recognition and treatment...
  4. ncbi Autoimmune factor VIII inhibitors
    R K Pruthi
    Department of Internal Medicine and Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Hematol 6:314-22. 1999
    ..Future laboratory and clinical studies are necessary for advancement of pathophysiologic knowledge and therapeutic options for patients with this uncommon but clinically important disorder...
  5. ncbi Sensitivity and specificity of denaturing high-pressure liquid chromatography for unknown protein C gene mutations
    M R Taliani
    Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Genet Test 5:39-44. 2001
    ..DHPLC is a rapid, automated, sensitive and specific screening method for unknown mutations within the PROC gene, and may be a useful screening method for unknown mutations within other genes...
  6. ncbi A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry
    D Chen
    Special Coagulation Laboratory, Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Thromb Haemost 6:323-30. 2008
    ..However, current manual or automated VWF:RCo assay methods have relatively poor operating characteristics. Our goal was to develop and validate a simple, accurate, specific and sensitive platelet-based VWF:RCo assay...
  7. ncbi Fechtner syndrome: physiologic analysis of macrothrombocytopenia
    R D McBane
    Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Blood Coagul Fibrinolysis 11:243-7. 2000
    ..This case illustrates that 'giant' platelets are not universally present in Fechtner syndrome cases, although the platelets are enlarged. Finally, renal pathology other than Alport's nephropathy may be associated with this syndrome...
  8. ncbi Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates
    D Dingli
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Haemophilia 8:629-34. 2002
    ....
  9. ncbi Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor
    J E Sadler
    Howard Hughes Medical Institute, Washington University, St Louis, MO 63110, USA
    J Thromb Haemost 4:2103-14. 2006
    ..The clinical significance of this heterogeneity is under investigation, which may support further subdivision of VWD type 1 or type 2A in the future...